ReviewCurrent neurology and neuroscience reports2010
Therapeutic strategies for diabetic neuropathy.
Review in Current neurology and neuroscience reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Meta-analysis of methylcobalamin alone and in combination with prostaglandin E1 in the treatment of diabetic peripheral neuropathy.Endocrine · 2014Pooled it
- Enhanced glucose control for preventing and treating diabetic neuropathy.The Cochrane database of systematic reviews · 2012Pooled it
- Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy. A randomized, double-blind trial.Neurosciences (Riyadh, Saudi Arabia) · 2014Trial
- The glycocalyx, a novel key in understanding of mechanism of diabetic nephropathy: a commentary.Journal of diabetes and metabolic disorders · 2021Article
- Controlling the "Opioid Epidemic": A Novel Chemical Entity (NCE) to Reduce or Supplant Opiate Use for Chronic Pain.Journal of psychiatry and brain science · 2020Article
- Analysis of sphingolipid composition in human vitreous from control and diabetic individuals.Journal of diabetes and its complications · 2019Article
- Article
- Low-Dose Pulsatile Interleukin-6 As a Treatment Option for Diabetic Peripheral Neuropathy.Frontiers in endocrinology · 2017Review
- Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice.Journal of neurophysiology · 2016Article
- A Role for Insulin in Diabetic Neuropathy.Frontiers in neuroscience · 2016Review
- Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population.The Clinical journal of pain · 2015Article
- Combined effect of hydrogen sulphide donor and losartan in experimental diabetic nephropathy in rats.Journal of diabetes and metabolic disorders · 2015Article
- Advanced glycation end products and diabetic complications.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2014Review
- In vivo peripheral nervous system insulin signaling.Journal of the peripheral nervous system : JPNS · 2013Article
- Cell therapy for diabetic neuropathy using adult stem or progenitor cells.Diabetes & metabolism journal · 2013Article
- Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Ginsenoside Rb1 relieves glucose fluctuation-induced oxidative stress and apoptosis in Schwann cells.Neural regeneration research · 2012Article
- Article
- Emerging therapy for diabetic neuropathy: cell therapy targeting vessels and nerves.Endocrine, metabolic & immune disorders drug targets · 2012Review
- Insulin resistance in the nervous system.Trends in endocrinology and metabolism: TEM · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is the leading cause of peripheral neuropathy globally. Duration of diabetes, glycemic control, and preexisting cardiovascular risk factors independently correlate with the development and progression of diabetic peripheral neuropathy as well as cardiovascular autonomic neuropathy. The pathogenesis of diabetic neuropathy remains unclear, although insulin resistance, oxidative stress, mitochondrial dysfunction, abnormal glucose metabolism, advanced glycation end products, neurotrophic factors, and protein kinase C activation all may play a role. Strict glycemic control remains the only available treatment option, although other treatments are in development. Multiple options are available for symptom management. In this article, we review factors associated with development and progression of diabetic neuropathy and discuss available treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.